Phenotypes Associated with This Genotype

Genotype
MGI:5526972

• Allelic Composition: Tg(MMTV-rtTA)1Lach/0; Tg(tetO-PIK3CA*H1047R,-luc)2239Jjz/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary gland tumor incidence ( J:175839 )

♀ • females treated with doxycycline for 4 weeks exhibit increased mammary ductal side-branching and enlarged focal nodular structures filled with hyperproliferative cells characteristic of early neoplastic lesions

♀ • chronic doxycycline induction results in development of mammary tumors with 95% penetrance and a mean latency of 7 months

♀ • withdrawal of doxycycline from females bearing tumors results in tumor regression during the first week after doxycycline removal, with a reduction in cellular proliferation and increase in apoptosis

♀ • withdrawal of doxycycline from females bearing tumors for up to 6 months results in 33% of tumors showing complete regression to a nonpalpable state within 1-2 months after doxycycline withdrawal with no regrowth, while 64% of tumors partially regress but then resume growth without doxycline and 3% partially regress but do not resume growth

increased mammary adenocarcinoma incidence ( J:175839 )

♀ • mammary tumors of doxycycline treated females include adenocarcinomas and adenosquamous carcinomas

integument

increased mammary gland tumor incidence ( J:175839 )

♀ • females treated with doxycycline for 4 weeks exhibit increased mammary ductal side-branching and enlarged focal nodular structures filled with hyperproliferative cells characteristic of early neoplastic lesions

♀ • chronic doxycycline induction results in development of mammary tumors with 95% penetrance and a mean latency of 7 months

♀ • withdrawal of doxycycline from females bearing tumors results in tumor regression during the first week after doxycycline removal, with a reduction in cellular proliferation and increase in apoptosis

♀ • withdrawal of doxycycline from females bearing tumors for up to 6 months results in 33% of tumors showing complete regression to a nonpalpable state within 1-2 months after doxycycline withdrawal with no regrowth, while 64% of tumors partially regress but then resume growth without doxycline and 3% partially regress but do not resume growth

increased mammary adenocarcinoma incidence ( J:175839 )

♀ • mammary tumors of doxycycline treated females include adenocarcinomas and adenosquamous carcinomas

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:175839 )

♀ • females treated with doxycycline for 4 weeks exhibit increased mammary ductal side-branching and enlarged focal nodular structures filled with hyperproliferative cells characteristic of early neoplastic lesions

♀ • chronic doxycycline induction results in development of mammary tumors with 95% penetrance and a mean latency of 7 months

♀ • withdrawal of doxycycline from females bearing tumors results in tumor regression during the first week after doxycycline removal, with a reduction in cellular proliferation and increase in apoptosis

♀ • withdrawal of doxycycline from females bearing tumors for up to 6 months results in 33% of tumors showing complete regression to a nonpalpable state within 1-2 months after doxycycline withdrawal with no regrowth, while 64% of tumors partially regress but then resume growth without doxycline and 3% partially regress but do not resume growth

increased mammary adenocarcinoma incidence ( J:175839 )

♀ • mammary tumors of doxycycline treated females include adenocarcinomas and adenosquamous carcinomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:175839